These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4181038)

  • 1. [Studies on the hormonal activity and progestagenic properties of Ovosiston preparation].
    Krzywdziński K; Jedrzejewski M; Teter J
    Ginekol Pol; 1969 Jan; 40(1):41-52. PubMed ID: 4181038
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sequential therapy].
    Annee Endocrinol; 1967; 19():97-102. PubMed ID: 4173491
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biphasic therapy using Sequenz-Ovosiston for hormonal contraception].
    Ebeling K; Kühndel K; Rothe K; Canzler E
    Z Arztl Fortbild (Jena); 1971 Dec; 65(24):1275-8. PubMed ID: 4111418
    [No Abstract]   [Full Text] [Related]  

  • 4. [Advantage of the use of an estroprogestational drug: 3 mg of chlormadinone acetate + 100 mcg of mestranol in endocrine gynecology].
    Bernard I
    Bord Med; 1970; 3(7):1954-60. PubMed ID: 4195405
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experiences with a gestagen-estrogen preparation (AK 103=Aconcen)].
    Kalchauer B
    Ther Ggw; 1966 Jul; 105(7):938-9. PubMed ID: 4162578
    [No Abstract]   [Full Text] [Related]  

  • 6. [Sequential treatment. Experimental and clinical study].
    Di Paola G; Mendizábal A; Usubiaga I; Ortega F
    Rev Argent Endocrinol Metab; 1966 Sep; 12(3):158-72. PubMed ID: 4170552
    [No Abstract]   [Full Text] [Related]  

  • 7. [Menstruation disorders due to Ovosiston medication].
    Kühndel K; Ebeling K; Rothe K
    Dtsch Gesundheitsw; 1971 Jan; 26(3):109-13. PubMed ID: 4106361
    [No Abstract]   [Full Text] [Related]  

  • 8. [Combined estrogen-progestagen-therapy in menstruation anomalies].
    Akasu F
    Arch Gynakol; 1971 Jun; 211(1):191-3. PubMed ID: 4103779
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical experience with the preparation Ovosiston with special reference to the cervix factor and vaginal cytology].
    Müller R; Kempf HJ; Eckert L
    Zentralbl Gynakol; 1968 Nov; 90(46):1545-55. PubMed ID: 4179333
    [No Abstract]   [Full Text] [Related]  

  • 10. [Chlormadinone therapy of menstruation disorders].
    Stanev S; Trepechov S
    Akush Ginekol (Sofiia); 1973; 12(2):110-5. PubMed ID: 4128262
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comparative cytological and histological studies following the use of an ovulation inhibiting estrogen-gestagen combination (Ovositon)].
    Krause W; Böhm W; Müller W
    Gynaecologia; 1968; 166(5):432-45. PubMed ID: 4179218
    [No Abstract]   [Full Text] [Related]  

  • 12. A new progestogen-estrogen combination for gynecologic therapy and contraception.
    Linthorst G
    Int J Fertil; 1966; 11(1):35-45. PubMed ID: 5936282
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical results of Lunarol, synthetic corpus luteum and follicle hormones preparation with special reference to corpus luteum insufficiency and amenorrhea].
    Iizuka R; Koi H; Saga M; Shibuya T; Hongo K
    Sanfujinka No Jissai; 1970; 19(3):322-30. PubMed ID: 4192774
    [No Abstract]   [Full Text] [Related]  

  • 14. ["Turignost" for early pregnancy test and short treatment of secondary amenorrhea].
    Müller R
    Dtsch Gesundheitsw; 1970 Feb; 25(6):252-4. PubMed ID: 4108414
    [No Abstract]   [Full Text] [Related]  

  • 15. [LH excretion during the ovulatory cycle and during therapy with various estrogen-gestagen combinations].
    Göretzlehner G; Wilken H
    Endokrinologie; 1972 Nov; 60(3):302-8. PubMed ID: 4121480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Histologic and colpocytologic aspects of the endometrium associated with HMG and HCG therapy].
    Cianci S; Di Leo S; Marotta N
    Minerva Ginecol; 1968 Sep; 20(17):1449-51. PubMed ID: 5739904
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical application of Sophia-A, combined low-dosage preparation of norethisterone and mestranol].
    Akasu F; Akasofu K; Hayashi I; Fujii I; Shimada H
    Horumon To Rinsho; 1969 Oct; 17(10):871-5. PubMed ID: 5390548
    [No Abstract]   [Full Text] [Related]  

  • 18. [CLINICAL USE OF A NEW ORAL PROGESTOGEN: CHLORMADINONE].
    DELCORRAL F; ARTUZ A; SALCEDO CA; ERAZO JV; ANGEL G
    Rev Colomb Obstet Ginecol; 1963; 14():605-23. PubMed ID: 14117499
    [No Abstract]   [Full Text] [Related]  

  • 19. [Use of Ovosiston in prevention of bleeding after electroconization].
    Malachowski Z; Kaliński R
    Pol Tyg Lek; 1970 Jul; 25(30):1138-9. PubMed ID: 4194911
    [No Abstract]   [Full Text] [Related]  

  • 20. [Experiences with different doses of Ovosiston preparations within the scope of marital and sexual counseling. Individual therapy with oral contraceptives].
    Ebeling K; Kühndel K; Rothe K
    Dtsch Gesundheitsw; 1971 Jan; 26(1):31-4. PubMed ID: 4106517
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.